GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2011 SENATE BILL 4
AN ACT TO ADD SYNTHETIC CANNABINOIDS TO THE LIST OF CONTROLLED
SUBSTANCES, WHICH MAKES THE UNLAWFUL POSSESSION, MANUFACTURE,
OR SALE OR DELIVERY OF SYNTHETIC CANNABINOIDS CRIMINAL OFFENSES.
The General Assembly of North Carolina enacts:
SECTION 1. G.S. 90-89 is amended by adding a new subdivision to read:
"§ 90-89. Schedule I controlled substances.
This schedule includes the controlled substances listed or to be listed by whatever official
name, common or usual name, chemical name, or trade name designated. In determining that a
substance comes within this schedule, the Commission shall find: a high potential for abuse, no
currently accepted medical use in the United States, or a lack of accepted safety for use in
treatment under medical supervision. The following controlled substances are included in this
Synthetic cannabinoids. – Any material, compound, mixture, or preparation
that is not listed as a controlled substance in Schedule II through VI, is not
an FDA approved drug, and contains any quantity of the following
substances, their salts, isomers (whether optical, positional, or geometric),
homologues, and salts of isomers and homologues, unless specifically
excepted, whenever the existence of these salts, isomers, homologues, and
salts of isomers and homologues is possible within any of the specific
chemical designations listed below in this subdivision:
3-(1-naphthoyl)indole structure with substitution at the nitrogen atom
of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
2-(4-morpholinyl)ethyl group, whether or not further substituted in
the indole ring to any extent and whether or not substituted in the
naphthyl ring to any extent. Some trade or other names: JWH-015,
JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200,
1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the
nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl
or 2-(4-morpholinyl)ethyl group whether or not further substituted in
General Assembly of North Carolina Session 2011
the indole ring to any extent and whether or not substituted in the
3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen
atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl
or 2-(4-morpholinyl)ethyl group whether or not further substituted in
the pyrrole ring to any extent, whether or not substituted in the
naphthyl ring to any extent. Another name: JWH-307.
naphthylideneindene structure with substitution at the 3-position of
the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
2-(4-morpholinyl)ethyl group whether or not further substituted in
the indene ring to any extent, whether or not substituted in the
3-phenylacetylindole structure with substitution at the nitrogen atom
of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
2-(4-morpholinyl)ethyl group whether or not further substituted in
the indole ring to any extent, whether or not substituted in the phenyl
ring to any extent. Some trade or other names: SR-18, RCS-8,
2-(3-hydroxycyclohexyl)phenol structure with substitution at the
5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl
or 2-(4-morpholinyl)ethyl group whether or not substituted in the
cyclohexyl ring to any extent. Some trade or other names: CP 47,497
Benzoylindoles. Any compound containing a 3-(benzoyl)indole
structure with substitution at the nitrogen atom of the indole ring by
an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group
whether or not further substituted in the indole ring to any extent and
whether or not substituted in the phenyl ring to any extent. Some
trade or other names: AM-694, Pravadoline (WIN 48,098), RCS-4.
2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,
4-benzoxazin-6-yl]-1-napthalenylmethanone. Some trade or other
(6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)
- 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol 7370. Some trade or
SECTION 2. This act becomes effective December 1, 2011, and applies to
offenses committed on or after that date.
European Journal of Cancer 36 (2000) 1473±1478Recommendations on cancer screening in the European UnionAdvisory Committee on Cancer Prevention *Received 10 January 2000; accepted 22 February 2000excluding non-melanoma skin cancer, occurred in theEuropean Union in 1995. Of these, 2% were cervicalScreening allows the detection of cancers at an earlycancers, 13% breast cancers, 13% colorectal
_________________________________________________________________________________________________ Reasons for Slow Development of Antimycotic Therapeutic Agents Systemic fungal infections until recently have been considered rare. Economics of drug companies traditionally have been such that the cost of development and testing did not seem to warrant extensive efforts (dramatic change